Recurrent or Refractory Ascites — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Ascites refer to the abnormal accumulation of fluid within the peritoneal cavity, primarily associated with cirrhosis and often indicating the transition from compensated to decompensated cirrhosis. Refractory ascites (RA) is a term defined by the International Club of Ascites (ICA) as ascites that recur within 4 weeks after large-volume paracentesis (LVP) and are resistant to medical therapy. Recurrent ascites, defined as ascites recurring at least three times within 12 months, impact survival differently than RA, and its effects on survival are yet unknown. Refractory ascites, occurring in 5%–10% of all patients with cirrhotic ascites, is associated with a high mortality rate, with an average 1-year survival rate of around 50%. Large-volume paracentesis, the primary treatment for refractory ascites, involves directly aspirating more than 5 liters of ascites. While LVP can rapidly control massive ascites and reduce hospital stays compared to diuretics, it does not affect the mortality rate. Patients with refractory ascites may require repeated paracentesis, leading to poor compliance, reduced quality of life, and increased risks of complications such as paracentesis-induced circulatory dysfunction (PICD), bleeding, and infections. Individuals with a blood platelet count below 50,000/mm3, those classified as Child-Pugh class C, and those with a history of alcoholism are at an elevated risk of developing PICD.
Thelansis’s “Recurrent or Refractory Ascites Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent or Refractory Ascites treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Recurrent or Refractory Ascites across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Recurrent or Refractory Ascites Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
